Grant of Options

RNS Number : 6451N

Alliance Pharma PLC

01 October 2021

 

For immediate release

1 October 2021

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over an aggregate of 565,776 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below.

Peter Butterfield, Chief Executive Officer, has been awarded 29,182 approved and 139,943 unapproved share options under the Company's 2015 Share Option Plan; and, 180,970 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.

Andrew Franklin, Chief Financial Officer, has been awarded 115,000 unapproved share options under the Company's 2015 Share Option Plan; and, 100,681 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.

The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 102.8p, being the closing mid-market price on 28^th of September 2021, and become exercisable on 29^th of September 2024, being the third anniversary of the date of the grant. The awards granted under the 2019 Long Term Incentive Plan have been granted at nil-cost and also become exercisable on 29^th of September 2024.

The vesting of these awards is subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.

The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:

Name	Share Options granted	Total no. of options over ordinary shares now held
Peter Butterfield	350,095	3,345,548
Andrew Franklin	215,681	2,069,192

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by person discharging managerial responsibilities.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Peter Butterfield
2	Reason for the notification
a)	Position/status	Chief Executive Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		102.8p	169,125
		Nil	180,970
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Grant of 169,125 options to acquire shares of 1p each at £1.028 per share at an aggregate exercise value of £173,860.50. Grant of 180,970 options to acquire ordinary shares of 1 pence each at nil-cost.
f)	Date of the transaction	29 September 2021
g)	Place of the transaction	Outside of trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Andrew Franklin
2	Reason for the notification
a)	Position/status	Chief Financial Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		102.8p	115,000
		Nil	100,681
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Grant of 115,000 options to acquire shares of 1 pence each at £1.028 per share at an aggregate exercise value of £118,220. Grant of 100,681 options to acquire ordinary shares of 1 pence each at nil-cost.
f)	Date of the transaction	29 September 2021
g)	Place of the transaction	Outside of trading venue

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black

Investec Bank plc	+ 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END

 

 

MSCVBLFXFKLLBBE